BioPrism: An optical nanoparticle sorting assay

Optofluidics公司提议开发一种名为BioPrism的新型蛋白质结合检测平台。Bioprism是一种可复用的、无标签的、基于头的结合试验。该系统将是体外分子诊断、治疗开发和分子生物学研究的理想选择。制药行业对更具成本效益的高通量检测方法的需求一直存在，为了找到一种有效的药物，制药行业通常要测试数百万种化合物（到2017年，市场规模将达到199亿美元）。分子结合分析是蓬勃发展的生物标志物体外诊断领域的基础（到2014年在美国将达到200亿美元）。市场上有几种高度复用的基于珠子的平台，但这些系统需要二次标签，这是昂贵的，并且增加了分析步骤。也有成功的商业系统可以进行无标签蛋白质结合测量；然而，它们很少或根本没有多路复用能力。我们建议将这两个系统的最佳元素结合到生物主义中。BioPrism将使用康奈尔大学Erickson实验室开发的纳米级光学器件（光子学），目前由Optofluidics公司商业化。该平台采用微流控流动池，将载珠样品注入其中，利用基于尺寸的光子分离技术区分裸纳米珠和蛋白结合纳米珠。蛋白质包被的纳米球由于起始纳米球的体积小，其尺寸显著增加。从不同颜色的荧光纳米粒子开始，每种颜色对应不同的探针，这种方法可以很容易地复用。珠子的大小将决定分析物是否结合，珠子的荧光指示哪个探针捕获了目标。在这个一期项目中，我们将制造我们的BioPrism芯片，使用现成的纳米颗粒对系统进行表征，进行结合试验以检测小鼠IgG的结合，并对设备设计进行数值模拟以优化性能。在第二阶段，我们将专注于分析开发和“可运输”生物系统的设计和构建。

DESCRIPTION: Optofluidics Inc. proposes to develop a novel protein-binding assay platform called the BioPrism. The Bioprism is a multiplexable, label-free, bead-based binding assay. The system will be ideal for in vitro molecular diagnostics, therapeutic development and molecular biology research. The need for more cost-effective high throughput assays is ever present in the pharmaceutical industry, which routinely tests millions of compounds in an effort to find a single effective drug ($19.9B Market by 2017). Molecular binding assays are the basis of the booming biomarker in-vitro diagnostics field ($20B in the US by 2014). There are several highly multiplexed bead-based platforms in the market, but these systems require secondary labels which are expensive and add steps to the assay. There are also successful commercial systems that do label-free protein binding measurements; however they have very little or no multiplexing capability. We propose to combine the best elements from both systems into the BioPrism. The BioPrism will use nanoscale optical devices (photonics) developed in the Erickson Lab at Cornell University and currently being commercialized by Optofluidics. Using a microfluidic flow cell, into which a bead-laden sample is injected, the platform can distinguish between bare nanobeads and protein-bound nanobeads using size- based photonic separation. Protein coated nanobeads significantly increase in size due to the small volume of the starting nanobead. By starting with fluorescent nanoparticles of different colors, where each color corresponds to a different probe, the method can be easily multiplexed. The size of the bead will determine whether analytes have bound and the fluorescence of the bead indicates which probe captured a target. In this Phase I project, we will manufacture our BioPrism chips, characterize the system using off-the-shelf nanoparticles, carry out binding assays to detect the binding of mouse IgG and carry out numerical simulations on the device design to optimize performance. In Phase II, we will focus on assay development and the design and construction of a "shippable" BioPrism system.